Impact investing: the blood test that could screen early-stage cancers
Regnan’s impact investment team believes ‘liquid biopsy’ technology could grow into a $US20 billion to $100 billion market. Regnan analyst Maxine Wille explains Blood tests could diagnose cancer and disease…